Location of Repository

Preclinical studies of targeted α therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2

By B J Allen, Z Tian, S M A Rizvi, Y Li and M Ranson
Topics: Experimental Therapeutics
Publisher: Nature Publishing Group
OAI identifier: oai:pubmedcentral.nih.gov:2377077
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (1992). (2002b) 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in xenograft animal model.
    2. (1999). An 225Ac/ 213Bi generator system for therapeutic clinical applications: construction and operation. Appl Rad Isot 50: 895–904
    3. (1992). Antitumour activity of the type 1 plasminogen activator inhibitor and cytotoxic conjugate in vitro. Cancer Res 52: 5829–5832 Jankun J
    4. (1995). Biochemistry, cellular and molecular biology and clinical aspects of plasminogen activator inhibitor type-2.
    5. (2000). Delivery of the aemitting radioisotope bismuth-213 to solid tumours by a single-chain Fv and diabody molecules.
    6. (2001). Preclinical targeted a therapy for subcutaneous melanoma.
    7. Ranson M (2001a) In vitro and preclinical targeted a therapy for melanoma, breast, prostate and colorectal cancers.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.